Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines

Cancer Research

Volumn 61, Issue 16, 2001, Pages 6185-6193

  Keshelava, Nino ^a,b   Zuo, Juan J ^a,b   Chen, Ping ^a,b   Waidyaratne, Sitara N ^a,b   Luna, Marian C ^a,b   Gomer, Charles J ^a,b   Triche, Timothy J ^a,b   Reynolds, C Patrick ^a,b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MELPHALAN; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; GENE MUTATION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; NEUROBLASTOMA; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DRUG RESISTANCE, MULTIPLE; ETOPOSIDE; GENE AMPLIFICATION; HUMANS; MELPHALAN; MUTATION; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS, VIRAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; REPRESSOR PROTEINS; TRANS-ACTIVATION (GENETICS); TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035881581     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid
2. Treatment of high-risk solid tumors of childhood with intensive therapy and autologous bone marrow transplantation
3. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy
4. p53: Puzzle and paradigm
5. Twenty years of p53 research: Structural and functional aspects of the p53 protein
6. p53 and the Li-Fraumeni syndrome
7. bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis
8. p53 status and the efficacy of cancer therapy in vivo
9. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems
10. Human lymphoblastoid cell lines expressing mutant p53 exhibit decreased sensitivity to cisplatin-induced cytotoxicity
11. p53 gene status and chemosensitivity of childhood acute lymphoblastic leukemia cells to Adriamycin
12. Chemotherapy-induced apoptosis in melanoma cells is p53 dependent
13. De novo deletions of p53 gene and wild-type p53 correlate with acquired cisplatin-resistance in human osteosarcoma OST cell line
14. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer
15. Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: Spontaneously mutant selection
16. Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation
17. The Walter Hubert lecture-molecular epidemiology of human cancer: Insights from the mutational analysis of the p53 tumour-suppressor gene
18. Low frequency of the p53 gene mutations in neuroblastoma
19. Mutation of the p53 gene in neuroblastoma and its relationship with N-myc amplification
20. Concomitant p53 mutation and MYCN amplification in neuroblastoma
21. Absence of p53 gene mutations in primary neuroblastomas
22. No TP53 mutations in neuroblastomas detected by PCR-SSCP analysis
23. Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas
24. Cytoplasmically sequestered wild-type p53 protein in neuroblastoma is relocated to the nucleus by a C-terminal peptide
25. The p53 signal transduction pathway is intact in human neuroblastoma despite cytoplasmic localization
26. Wild-type p53 can induce p21 and apoptosis in neuroblastoma cells but the DNA damage-induced G1 checkpoint function is attenuated
27. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)-retinamide in neuroblastoma cell lines
28. No germline TP53 mutations detected in familial and bilateral testicular cancer
29. Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array
30. Analysis of p53 transactivation through high-affinity binding sites
31. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53
32. Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines
33. Biological classification of cell lines derived from human extra-cranial neural tumors
34. Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in melphalan-resistant neuroblastoma cell line
35. Expression of protein gene product 9.5 and tyrosine hydroxylase in childhood small round cell tumors
36. Amplification of a gene encoding a p53-associated protein in human sarcomas
37. Multiple drug-effect analysis (program B)
38. Loss of function and p53 protein stabilization
39. Role of p53 in the regulation of irradiation-induced apoptosis in neuroblastoma cells
40. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
41. p53 mutations increase resistance to ionizing radiation
42. Characterization of p53 mutants identified in human tumors with a missense mutation in the tetramerization domain
43. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN
44. Alkylator resistance in human B lymphoid cell lines: (1). Melphalan accumulation, cytotoxicity, interstrand-DNA-crosslinks, cell cycle analysis, and glutathione content in the melphalan-sensitive B-lymphocytic cell line (WIL2) and in the melphalan-resistant B-CLL cell line (WSU-CLL)
45. Clinical studies of reversal of drug resistance based on glutathione
46. Coordinated induction of MRP/GS-X pump and γ-glutamylcysteine synthetase by heavy metals in human leukemia cells
47. Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells
48. The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein
49. Stabilization of the MDM2 oncoprotein by mutant p53
50. p53 inactivation by HPV16 E6 results in increased mutagenesis in human cells
51. Abrogation of p53 function by transfection of HPV16 E6 gene enhances the resistance of human diploid fibroblasts to ionizing radiation
52. Testing the role of p53 in the expression of genetic instability and apoptosis in ataxia-telangiectasia
53. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas
54. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers
55. p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma
56. Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line
57. Comparison of TP53 mutations identified by oligonucleotide microarray and conventional DNA sequence analysis
58. Microsatellite instability at selected tetranucleotide repeats is associated with p53 mutations in non-small cell lung cancer
59. Synergistic cytotoxicity in solid tumor cell lines between N-(4-Hydroxyphenyl)retinamide and modulators of ceramide metabolism
60. Synergism of buthionine sulfoximine and melphalan against neuroblastoma cell lines derived after disease progression
61. Immunotherapy of neuroblastoma
62. p53 gene status, and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma
63. p53 mutations do not predict response to paclitaxel in metastatic nonsmall cell lung carcinoma